文献速递系统性红斑狼疮

系统性红斑狼疮患者28年骨折风险分析

Fracture risk in systemic lupus erythematosus patients over 28 years.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究回顾性分析250例SLE患者28年随访数据,中位随访17年,发现28例(11.2%)发生脆性骨折,平均首次骨折年龄51±16岁。糖皮质激素平均剂量6.20 mg/天,骨折组日剂量更低(5.36 vs 6.23 mg/天)但累积剂量更高(25.19 vs 20.96 g),差异均无统计学意义(P=0.127和0.229)。Cox回归显示诊断时年龄较大、骨质疏松和继发性甲旁亢与脆性骨折相关,糖皮质激素剂量与骨折无显著关联。

要点

  • SLE患者28年随访中11.2%发生脆性骨折,平均首次骨折年龄51岁。
  • 糖皮质激素日剂量或累积剂量与脆性骨折无显著关联。
  • 诊断时年龄较大、骨质疏松和继发性甲旁亢与脆性骨折相关。

核心结论

  • 在该SLE队列中未发现糖皮质激素治疗与脆性骨折之间存在显著关联,但需前瞻性研究纳入更多未用糖皮质激素患者以确认。

研究设计与样本

  • 回顾性分析28年间就诊于University College Hospital的SLE患者,收集连续激素剂量、双能X线吸收扫描和脆性骨折数据,共250例,中位随访17年。

主要发现

  • 28例(11.2%)诊断脆性骨折,平均±s.d.首次骨折年龄51±16岁。
  • 94%患者接受糖皮质激素,平均剂量6.20 mg/天。
  • 骨折组平均日剂量更低(5.36 vs 6.23 mg/天)但中位累积剂量更高(25.19 vs 20.96 g),差异无统计学意义(P=0.127和0.229)。
  • 93%患者接受维生素D,85%接受钙剂。
  • Cox回归显示诊断时年龄较大、骨质疏松和继发性甲旁亢与脆性骨折相关,糖皮质激素剂量与脆性骨折发生无显著关联。

关键数值与推荐

  • EULAR指南推荐SLE管理中将慢性糖皮质激素剂量减至≤7.5 mg/天以最小化骨折风险。
  • 骨折患者中22例接受双膦酸盐治疗,2例地舒单抗,2例特立帕肽。

临床怎么用

  • SLE患者应关注诊断时年龄较大、骨质疏松和继发性甲旁亢等骨折风险因素。
  • 尽管本队列未显示激素剂量与骨折显著相关,仍应遵循EULAR推荐将慢性激素剂量控制在≤7.5 mg/天。

局限性

  • 为回顾性分析,样本量有限(250例),且缺乏未接受糖皮质激素治疗的对照组,需前瞻性研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Chronic glucocorticoid use is complicated by osteoporosis and increases the risk of fragility fractures. EULAR guidelines on SLE management recommend reducing chronic glucocorticoid dosage to ≤7.5 mg/day to minimize this risk. We examined the relationship of glucocorticoid dose to fragility fracture risk in a cohort of SLE patients. METHODS: Retrospective analysis of SLE patients attending University College Hospital over 28 years was undertaken. Collected data included consecutive steroid dose, dual-energy X-ray absorptiometry scans and fragility fractures. RESULTS: We collected data on 250 patients with a median of 17 years' follow-up. Fragility fractures were diagnosed in 28 (11.2%) patients and the mean ± s.d. age of first fracture was 51 ± 16 years. A total of 94% received glucocorticoids, the average dose being 6.20 mg/day. Patients with fragility fractures had a lower average daily dose (5.36 vs 6.23 mg/day) but a higher median cumulative dose (25.19 vs 20.96 g). These differences were not significant (P = 0.127 and 0.229, respectively). Some 93% of patients received vitamin D, and 85% received calcium. Cox regression analysis showed older age at SLE diagnosis, osteoporosis and secondary hyperparathyroidism were associated with fragility fractures. Glucocorticoid dose was not significantly associated with the occurrence of fragility fractures. Twenty-two patients with fractures were treated with bisphosphonates, two with denosumab and two with teriparatide. CONCLUSIONS: We found no significant association between glucocorticoid treatment and fragility fractures in our group of patients; however, a prospective study including more patients not treated with CS would be necessary to confirm these results.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Garelick D, Pinto SM, Farinha F, et al. Fracture risk in systemic lupus erythematosus patients over 28 years. Rheumatology (Oxford). 2021. PMID: 33221918. doi:10.1093/rheumatology/keaa705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。